NRx Pharmaceuticals is seeking regulatory approval from the FDA for its drug candidates, NRX-100 and NRX-101.
4 reports, 2 independent
Updated Sat 00:00
No new developments lately
- Reports
- 4
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
NRx Pharmaceuticals is seeking regulatory approval from the FDA for its drug candidates, NRX-100 and NRX-101.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.FDA approved NRx's drug application and reviewed the drug-device combination component.1 source
NRx seeks FDA approval for drug candidates NRX-100 and NRX-101.1 source
Keep exploring
The entities involved
Related events
- Argenx SE announced it is listed on Nasdaq and is seeking FDA priority review and approval.
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- Both the FDA and the European Medicines Agency govern drug approval processes.
- FDA approval expands patient access to therapies for ACCORD.
- FDA approval supports NDA submission in Aurora.
Coverage
Newest first; wire copies grouped- dailypolitical.com
- NewMediaWireIBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Charts Dual-Path for NRX-100 This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to t
- NewMediaWireIBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Positioning at the Forefront of Next-Gen Treatment This article was published by IBN, a multifaceted communications organization engaged in connecting
- Unknown outlet